Active	Status	Sponsor type	Region	Phase	Filter
10 Active 7 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Nicholls, Stephen
ASPIRE-AF, NCT03968393 / 2019-001336-62: Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery	Recruiting	4	2270	Europe, Canada, RoW	Non-vitamin K oral anticoagulant (NOAC), Apixaban, Dabigatran, Edoxaban, Rivaroxaban	Population Health Research Institute, Hamilton Health Sciences Corporation	Stroke, Atrial Fibrillation	12/26	12/28
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events	Completed	2	233	Europe, Japan, US, RoW	LY3473329, Placebo	Eli Lilly and Company	Lipoprotein Disorder	03/24	03/24
SOCRATES, NCT05180942: Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS	Recruiting	2	180	RoW	Atorvastatin Calcium 40Mg Tab	Monash University, National Health and Medical Research Council, Australia	Melanoma, Atherosclerosis	06/26	06/26
ADVANCE-DCB, NCT05521542: Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease	Recruiting	N/A	40	RoW	SirPlux Duo™ Dual-API Coated PTCA Balloon Catheter	Advanced NanoTherapies, Monash University, Cardiovascular Research Foundation, New York	Coronary Artery Disease	12/24	03/27
GOAL-ASIA, NCT05325034: Guideline Oriented Approach to Lipid Lowering in Asia-Pacific	Recruiting	N/A	2000	Japan, RoW	Early Intervention	Stephen Nicholls, Amgen	Cardiovascular Diseases, Acute Coronary Syndrome, Atherosclerosis, Hypercholesterolemia	12/24	12/24
ASCERTAIN, NCT05834673: VICTORION- Implementation Study (v-)	Terminated	N/A	6	RoW	SMS messages, Monthly Text Messages, Telephone-based support calls, Nurse Support Calls, GP Education	Monash University, Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease (ASCVD), Coronary Heart Disease (CHD), Cerebrovascular Disease, Peripheral Arterial Disease (PAD)	12/24	12/24
Gaal, William Van
RESTORE-MI, NCT03998319: A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.	Recruiting	3	445	RoW	Tenecteplase (1/3 systemic weight based dose), TNKase, Sterile water for injection (WFI)	University of Sydney, Genentech, Inc.	STEMI, Elevated IMR (>32)	12/24	12/26
Sumner, Andrew
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29